COLL Q1 2019 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q1 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$75M+16.9% YoY

Gross Profit

$25M34.0% margin

Operating Income

-$10M-13.4% margin

Net Income

-$10M-13.0% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+1.5%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$12M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$294M

Total Liabilities

$208M

Stockholders' Equity

$86M

Cash & Equivalents

$135M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75M	$64M	+16.9%
Gross Profit	$25M	$21M	+22.8%
Operating Income	-$10M	-$13M	+24.3%
Net Income	-$10M	-$19M	+48.0%

Revenue Segments

Nucynta

$49M66%

Xtampza

$25M34%